Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of EML4-ALK Lung Cancer

被引：0
|
作者：
Arai, S. [1 ]
Takeuchi, S. [1 ]
Fukuda, K. [1 ]
Nishiyama, A. [1 ]
Tanimoto, A. [1 ]
Taniguchi, H. [1 ]
Satouchi, M. [2 ]
Nanjo, S. [1 ]
Katayama, R. [3 ]
Nishio, M. [4 ]
Zheng, M. [5 ]
Wu, Y. [6 ,7 ]
Yano, S. [1 ]
机构：
[1] Kanazawa Univ, Canc Res Inst, Kanazawa, Ishikawa, Japan
[2] Hyogo Canc Ctr, Akashi, Hyogo, Japan
[3] Japanese Fdn Canc Res, Canc Chemotherapy Ctr, Tokyo, Japan
[4] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[5] Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[6] Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[7] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
leptomeningeal carcinomatosis; alectinib resistance; Osimertinib;
D O I：
10.1016/j.jtho.2019.08.1841
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.14-56
引用
收藏
页码：S852 / S853
页数：2
相关论文
共 50 条
  • [31] Targeting the ARID1A mutations overcomes primary resistance to ALK inhibitors in EML4-ALK positive NSCLC
    Oh, Seung Yeon
    Lee, You Won
    Lee, Eun Ji
    Kim, Ju Young
    Park, Sewon
    Park, Ju Yeon
    Choi, Su-Jin
    Yu, Mi Ra
    Aum, Sowon
    Lee, Jiyun
    Kim, Chang Gon
    Lee, Jii Bum
    Lim, Sun Min
    Hong, Min Hee
    Yun, Mi Ran
    Cho, Byoung Chul
    CANCER RESEARCH, 2023, 83 (07)
  • [32] Colorectal Cancer with EML4-ALK Fusion Gene Response to Alectinib: A Case Report and Review of the Literature
    Hsiao, Sheng-Yen
    He, Hong-Lin
    Weng, Teng-Song
    Lin, Cheng-Yao
    Chao, Chien-Ming
    Huang, Wen-Tsung
    Tsao, Chao-Jung
    CASE REPORTS IN ONCOLOGY, 2021, 14 (01): : 232 - 238
  • [33] Dividing and conquering the variation among variants in EML4-ALK lung cancer
    Bivona, Trever G.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S369 - S370
  • [34] Clinico-pathologic features of lung cancer with EML4-ALK translocation
    Mitsudomi, T.
    Suda, K.
    Tomizawa, K.
    Yatabe, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer
    Garces, Aimie E.
    Al-Hayali, Mohammed
    Lee, Jong Bong
    Li, Jiaxin
    Gershkovich, Pavel
    Bradshaw, Tracey D.
    Stocks, Michael J.
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (03): : 316 - 321
  • [36] Hope without hype: EML4-ALK inhibition for treatment of lung cancer
    Govindan, Ramaswamy
    LANCET ONCOLOGY, 2011, 12 (11): : 983 - 984
  • [37] Discovery and clinical application of a novel oncogene, EML4-ALK, in lung cancer
    Mano, Hiroyuki
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) : S214 - S214
  • [38] A RATIONAL DIAGNOSTIC ALGORITHM FOR THE IDENTIFICATION OF EML4-ALK TRANSLOCATION IN LUNG CANCER
    Takamochi, Kazuva
    Oh, Shiaki
    Suzuki, Kenji
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S462 - S462
  • [39] PARACRINE RECEPTOR LIGANDS ACTIVATE BYPASS TRACTS AND CAUSE ALK INHIBITOR RESISTANCE IN EML4-ALK LUNG CANCER CELLS
    Yamada, Tadaaki
    Takeuchi, Shinji
    Nakade, Junya
    Nakagawa, Takayuki
    Nanjo, Shigeki
    Ebi, Hiromichi
    Nakamura, Takahiro
    Matsumoto, Kunio
    Soda, Manabu
    Mano, Hiroyuki
    Yano, Seiji
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S455 - S455
  • [40] EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib
    Matsuda, Hironari
    Hara, Munechika
    Iwakami, Shin-Ichiro
    Takahashi, Kazuhisa
    BMJ CASE REPORTS, 2021, 14 (04)
12345